Greece

Andrew Witty, head of GlaxoSmithKline (GSK), has publicly criticised Novo Nordisk for withdrawing products from Greece, following the introduction of a new pricing mechanism for pharmaceuticals.[1]... 2010-06-23

BMI View: The introduction of government price erosion mechanisms will accelerate across Europe, a view driven by need for fiscal austerity and supported by the actions of numerous... 2010-05-05

Greece's government has unveiled further details of the country's pharmaceutical pricing and reimbursement reform, which BMI believes could have a severely detrimental effect on market... 2010-03-19

BMI has introduced greater clarity to its core views for the Pharmaceuticals & Healthcare. Short-term core views concern the period through to the end of the 2011-2013 patent cliff,... 2010-03-15

BMI forecasts that pharmaceutical sales in Emerging Europe will grow by 125% over the next decade, representing a compound annual growth rate (CAGR) of 8.43%. With global sales projected... 2010-01-05

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has lodged a formal complaint with the European Commission (EC) over Greece's non-payment of debts. According... 2009-12-18

Greece's pricing and reimbursement environment is set for a period of transformation, which will see price freezes or reductions for originator drugs, the introduction of referencing... 2009-11-27

BMI believes that the Greek election victory for the socialist PASOK party on October 4 2009 marks a true opportunity to regain control of the state healthcare system, where years... 2009-11-09

BMI calculates the Greek medical device market to be worth EUR1.27bn (US$1.86bn) in 2008, making it one of the largest markets in Central and Eastern Europe (CEE). In total, spending... 2009-11-04

BMI's regional outlook for pharmaceutical companies in Emerging Europe has improved marginally, following an update to our Pharmaceuticals & Healthcare Business Environment Ratings.... 2009-10-30